← Back to Search

Adrenergic Agonist

Epinephrine for Diabetes (Epineprhine Trial)

Phase < 1
Recruiting
Led By Stephen Davis, MBBS
Research Sponsored by University of Maryland, Baltimore
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Healthy controls age 18-55 yr.
Body mass index >21 kg · m-2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline (pre glucose clamp) to end of experiment (time 240 minutes- 2 hours post intervention (glucose clamp))
Awards & highlights

Epineprhine Trial Summary

This trial will study the effects of epinephrine on the body, specifically how it regulates function and inflammation.

Who is the study for?
This trial is for healthy individuals aged 18-55 with a BMI over 21. Participants should not have any severe illnesses, infections, or heart problems. They must not be pregnant, breastfeeding, using tobacco, or have allergies to study medications. Volunteers need to agree to use contraception and cannot be on anticoagulants.Check my eligibility
What is being tested?
The trial studies how different doses of epinephrine affect blood vessel function and the balance between clotting and bleeding in healthy people. It aims to understand epinephrine's role in preventing low blood sugar levels in diabetes by comparing it with saline infusions.See study design
What are the potential side effects?
Potential side effects may include reactions at the infusion site, changes in blood pressure or heart rate, anxiety or nervousness, headache, tremor, and possible alterations in metabolic parameters due to epinephrine's wide range of actions.

Epineprhine Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
People who are healthy and between 18 and 55 years old.
Select...
Your body mass index is higher than 21 kg/m2.

Epineprhine Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline (pre glucose clamp) to end of experiment (time 240 minutes- 2 hours post intervention (glucose clamp))
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline (pre glucose clamp) to end of experiment (time 240 minutes- 2 hours post intervention (glucose clamp)) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Flow mediated dilation (FMD) of the brachial artery

Side effects data

From 2021 Phase 4 trial • 22 Patients • NCT04065451
10%
abdominal pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Epinephrine
No Epinephrine

Epineprhine Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Epinephrine infusion-0.06 ug/kg/minExperimental Treatment1 Intervention
Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.06 ug/kg/min
Group II: Epinephrine infusion-0.03 ug/kg/minExperimental Treatment1 Intervention
Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.03 ug/kg/min
Group III: Epinephrine infusion-0.015ug/kg/minExperimental Treatment1 Intervention
Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.015 ug/kg/min
Group IV: Saline infusionPlacebo Group1 Intervention
Hyperinsulinemic euglycemic glucose clamp with saline infusion
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Epinephrine
2014
Completed Phase 4
~3940

Find a Location

Who is running the clinical trial?

University of Maryland, BaltimoreLead Sponsor
685 Previous Clinical Trials
373,014 Total Patients Enrolled
4 Trials studying Diabetes
23,990 Patients Enrolled for Diabetes
Vanderbilt UniversityOTHER
703 Previous Clinical Trials
6,142,937 Total Patients Enrolled
7 Trials studying Diabetes
1,139 Patients Enrolled for Diabetes
Stephen Davis, MBBSPrincipal InvestigatorUniversity of Maryland, Baltimore

Media Library

Epinephrine (Adrenergic Agonist) Clinical Trial Eligibility Overview. Trial Name: NCT02692313 — Phase < 1
Diabetes Research Study Groups: Epinephrine infusion-0.015ug/kg/min, Epinephrine infusion-0.06 ug/kg/min, Epinephrine infusion-0.03 ug/kg/min, Saline infusion
Diabetes Clinical Trial 2023: Epinephrine Highlights & Side Effects. Trial Name: NCT02692313 — Phase < 1
Epinephrine (Adrenergic Agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02692313 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

For what purpose is Epinephrine typically employed?

"Epinephrine can be used to treat low blood pressure, an unresponsive slow heart rate, and an abnormal dilation of the pupil."

Answered by AI

Are there any open enrollment opportunities for this research project?

"If you consult clinicaltrials.gov, you'll see that this study is still looking for participants. It was originally posted on June 1st, 2016 but was updated most recently on April 8th, 2022."

Answered by AI

What is the precedent for Epinephrine clinical trials?

"As of right now, there are 33 on-going Epinephrine trials with 5 in the final Phase 3. A majority of these studies are centred in Baltimore, Maryland, but there are 52 locations in total running these Epinephrine trials."

Answered by AI

If a potential test subject is younger than 65, will they still be able to participate in this experiment?

"The age range for people who can enroll in this trial are those who are 18 years old or older, but younger than 55 years old."

Answered by AI
~3 spots leftby Feb 2025